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ABSTRACT
Objective: Traditionally, nursing homes have been associated with suboptimal drug therapy
and drug-related problems (DRPs). In contrast, less is known about drug safety in homecare.
The aim of this study was to describe and compare DRPs in older persons across two care set-
tings: nursing homes and home nursing care.
Design: Cross-sectional study using descriptive and inferential statistics.
Setting: Nursing homes (n¼ 5) and home nursing care units (n¼ 8) across nine municipalities in
the middle of Norway.
Participants: Multidisciplinary medication reviews for 61 nursing home residents and 93
patients receiving home nursing care performed over the 2013–2014 period, were mapped and
examined (N¼ 154).
Main outcome measures: DRPs classified by a Norwegian Classification Tool.
Results: In all, 740 DRPs were detected in the total sample, 227 in nursing homes and 513 in
home nursing care. DRPs were significantly higher among patients receiving home-based care
(Mean ¼5.5) compared to patients in nursing homes (Mean ¼3.7, p¼ 0.002). Among the prob-
lem categories, the need for additional drug was most frequent in nursing homes (p¼ 0.001),
while documentation discrepancies reached the highest numbers in patients receiving home
nursing care (p¼ 0.000). Additionally, patients in home nursing care had more problems con-
cerning adverse reactions (p¼ 0.060); however, this was not statistically significant. Differences
in DRP categories leading to changes in the patients’ medication lists were also discovered.
Conclusions: The frequency of unclear documentation and adverse reactions found in the
homecare setting is alarming. This is an important issue given the trend in aged care towards
caring people in their own homes. Further research is warranted to explore how different care
settings may influence the safety of pharmacotherapy for older persons.
KEY POINTS
Drug related problems are a significant cause of concern among patients receiving
home nursing care as well as for patients living in nursing homes. The findings of
this study showed that:
 Significantly more DRPs were detected among patients receiving home nursing
care than patients living in nursing homes.
 While patients living in nursing homes were often undermedicated, documentation
discrepancies were more frequent in home nursing care.
 DRP categories leading to changes on the medication lists differed between
the settings.
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Introduction
Drug regimens among patients in primary healthcare
settings are increasingly complex and potentially harmful
[1]. In this context, the majority of the patients are of
advanced age, have multiple chronic diseases and poly-
pharmacy [1–3]. This combination of factors renders this
population especially vulnerable to drug-related prob-
lems (DRPs), hospitalisation and death [4–6]. A DRP is
defined as “an event or circumstance involving drug
therapy that actually or potentially interferes with
desired health outcomes” [7]. While the incidence and
effects of potentially harmful medication therapy have
been studied extensively in nursing home populations
and hospitalised patients, data concerning DRPs in com-
munity-dwelling elderly populations is relatively scarce.
It is thought that the prevalence of inappropriate
drug prescribing among nursing home residents and
long-term care facilities is suggested to vary from
18.5% to 82.6% [8], and 14.7% to 28% among commu-
nity-dwelling older adults [9–11]. However, direct com-
parison is hampered because studies apply different
criteria for identifying DRPs or inappropriate prescrip-
tions. Halvorsen et al. [12] found significant differences
in the quality of medication prescribing in Norwegian
home nursing services as compared with nursing
homes. Their results indicated that while suboptimal
drug therapy is equally as prevalent in the homecare
setting as it is in nursing homes, there are differences
in the nature of these discrepancies.
Norway’s increasingly aging population challenges
the resources of an already overburdened healthcare
system. As such, homecare services are becoming crit-
ically important, not only to cut costs, but to satisfy
consumer preferences [13,14]. Patients in homecare
are increasingly old and frail, consume multiple medi-
cations and transfer frequently between different care
settings and therapists [13,15]. General practitioners
(GPs) and nurses responsible for these patients often
collaborate without physically working together and
may maintain separate medication lists for patients
they have in common. GPs also rely largely on nurses
to make assessments and to communicate their obser-
vations [16]. Other characteristics such as a high
degree of patient autonomy, problems with compli-
ance, increased workloads and situational variables
unique to each home can exert an environmental
influence on patient safety in general and on medica-
tion safety in particular [16–18].
The risk of DRP is largely a factor of the number of
drugs used, the presence of comorbidity and the
patient’s age [1]. Notwithstanding, factors implicit in
the care setting may also contribute to the incidence
of DRPs; however, to the best of our knowledge, no
studies have yet explored this important question.
Therefore, the aim of this study was to describe and
compare DRPs in older persons, identified by multidis-
ciplinary teams, across two care settings: nursing
homes and home nursing care.
Material and methods
Data for this study was based on a cross-sectional
study of DRPs identified through multidisciplinary
medication reviews performed for 154 patients. The
design was quantitative, and made use of descriptive
and inferential statistics.
Setting
The study population was recruited from nine munici-
palities representing both urban (> 5000 inhabitants)
and rural areas (<5000 inhabitants) in the middle of
Norway. From December 2013 to June 2014, these
municipalities participated in the Norwegian Patient
Safety Programme, “In Safe Hands,” which started as
a Campaign and has continued as a Programme
(2014–2019) [19]. Aiming to reduce DRPs and
enhance drug safety among patients in nursing
homes and home nursing care, the key intervention
in this programme is a structured medication review.
Health professionals (GPs, nurses and pharmacists)
from each of the municipalities were gathered for
seminars and workshops three times during the 7
months participation in the Programme. These semi-
nars described the procedure for performing the
medication reviews, based on national guidelines [20]
and the Integrated Medicines Management Model
(IMM-model) [21].
Multidisciplinary medication review
The medication review comprises a package of meas-
ures that involves several steps [21].
The first measure aims to identify patients who are
at risk for the development of DRPs and who have a
need for a medication review. Based on the guidelines
[20], the recommended criteria for review include old
age, polypharmacy, significant changes in the patient’s
health condition, a new diagnosis or recently pre-
scribed a new medication, readmission to hospital or
change between care levels. After the GP and the
nurse have identified a patient, the nurse collects
relevant patient data using a checklist focusing on
prescribed medication, diagnosis, symptoms, daily
2 S. A. DEVIK ET AL.
functioning and physical parameters (e.g., renal status,
weight, relevant blood samples). The medication
review also involves taking an accurate and up-to-date
inventory of all the medications the patient is taking
(i.e., medication reconciliation), which means checking
for discrepancies between the patient’s own list, the
physician’s list and the list administered by the nurs-
ing home or homecare. The collected information is
shared between the collaborating health personnel,
each of them whom is charged with identifying poten-
tial DRPs and for ensuring that the treatment complies
with national guidelines [22,23].
In the next step, the GP, the nurse and the pharmacist
attend at a case conference during which they discuss
the identified DRPs and the optimal treatment plan for
the patient. The GP is responsible for the final decision
on whether to act upon the identified DRPs. For
example, the team may opt to cease, replace or pre-
scribe additional medications. Alternatively, the team
might simply adjust the patient’s medication dose,
increase the level of monitoring required or correct docu-
mentation (these actions are reported as “acceptance” of
the identified DRPs in the results section). While this
process promotes multidisciplinary collaboration, [20],
pharmacists are not traditionally active members of
multidisciplinary teams in Norwegian nursing homes or
homecare [24]. For the purpose of this study, all but one
of the participating municipalities employed a pharma-
cist, who was collocated at either a hospital or a private
pharmacy. In the one non-employing municipality, the
GPs and nurses collaborated on identifying DRPs accord-
ing to the guidelines given by the Patient safety
Programme [20,21] without consulting a pharmacist.
Data collection
Three pharmacists from the research group retrieved
the documentation of the medication review from the
medical records and used a Norwegian classification
tool [23] to classify the DRPs. This tool classifies prob-
lems according to a hierarchical structure comprising
six main categories (drug choice, dosing, adverse reac-
tion, interaction, drug use and other) and 12 subcate-
gories (see Table 2). The pharmacists were restricted
to classifying DRPs already identified by the local
teams and they did not perform any control or re-
examination of the medication reviews.
Statistical analysis
SPSS (v.24) for MS Windows was used for the analysis.
Descriptive analysis of DRPs were performed, including
frequencies, mean, standard deviation (SD), median,
interquartile range (IQR), percentages, and 95%
confidence intervals (CI) where appropriate. The
Mann–Whitney U test, the Student’s t-test, and the
Chi-square test were conducted to detect differences
between patient groups. P-values greater than 0.05
were considered statistically significant.
Results
Characteristics of the sample
The sample consisted of 154 patients, 47 men and 107
women, and their ages ranged from 65 to 102 years.
Patients living in nursing homes were more likely to
reside in a rural municipality (p< 0.001), but no other
significant differences were found regarding age, gen-
der or number of regular drugs used. The median for
the number of regular drugs used in the total sample
was 8.0 (IQR =5.0). The minimum use was two drugs
and the maximum was 16. Most medication reviews
were performed by a GP, a nurse and a pharmacist in
collaboration, but in 13 of the 93 cases reviewed in
home nursing care, a GP and a nurse performed the
reviews without a pharmacist present. Characteristics
of the sample are given in Table 1.
Drug-related problems
In total, 740 DRPs were identified in the entire sample
(Mean =4.8, SD¼ 3.5). The most prevalent DRP catego-
ries identified in the total sample were “unclear doc-
umentation”1, and “unnecessary drug,” followed by
“need for additional drug,” and “inappropriate drug
choice.” Patients in home nursing care had significantly
more DRPs (Mean =5.5, SD¼ 4.0) than those living in
nursing homes (Mean =3.7, SD¼ 2.3). The categories
Table 1. Characteristics of the sample.
Characteristics
Total sample Nursing home Home nursing care
P-valueN¼ 154 n¼ 61 n¼ 93
Age, median (IQR) 87.0 (9.0) 86.0 (8.0) 87.0 (11.0) 0.813a
Male, n (%) 47 (30.5) 17 (27.9) 30 (32.3) 0.563b
Urban, n (%) 50 (32.5) 5 (8.2) 45 (48.4) 0.000b
Number of regular drugs, median (IQR) 8.0 (5.0) 8.0 (4.0) 9.0 (5.0) 0.308a
aMann–Whitney U
bChi-square test.
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“need for additional drug” and “unclear documentation”
differed significantly between these groups, of which
need for additional drug was most frequent in nursing
homes and unclear documentation was most frequent
in patients receiving home nursing care. Patients receiv-
ing home nursing care also had more problems with
adverse reactions, although this was not statistically sig-
nificant (See Table 2). Drugs classified in the nervous
system group (ATC2 N-group) were most commonly
involved in DRPs (psycholeptica/N05, analgesics/N02
and psychoanaleptica/N06). Drugs registered in the ATC
A-group (digestion and metabolism) were the second
most common (antacids/A02 most frequent). No differ-
ences were detected between the two care settings
with regard to which drugs were causing DRPs.
Within home nursing care, multidisciplinary teams
consisting of a GP and a nurse identified significantly
more DRPs than teams composed by a GP, a nurse
and a pharmacist (Median =8.0 vs. Median =4.0,
p< 0.013). Patients who had their medication
reviewed by a GP and a nurse (n¼ 13) did not use
more drugs than the rest of the sample in home nurs-
ing care. Unclear documentation was the most preva-
lent DRP found by teams consisting of only a GP and
a nurse. Among the 13 patients, 86 documentation
problems were found.
Acceptance of problems and changed
medication lists
At the medication reviews, the GPs accepted 518 of
the 740 identified problems (70% acceptance) and
changed their prescriptions accordingly, while 222
DRPs were rejected and led to no changes in the
medication lists. In nursing homes, a 100% acceptance
rate was seen according to “too low dose,”
“suboptimal dosing scheme” and “inappropriate use
by patient,” although these categories accounted for
relatively few problems. In home nursing care, a 100%
acceptance rate was seen for the categories:
“suboptimal dosing scheme,” “inappropriate use by
health personal,” and “not classified/complex prob-
lem,” but again, these problems were few in numbers.
For a more detailed breakdown of the acceptance rate
for each category, see Table 3.
Among the categories that accounted for a high
numbers of problems, physicians in both settings were
most inclined to change their prescriptions according
to “need for additional drug” and “unnecessary drug,”
but less so for “inappropriate drug choice.” In nursing
homes, the categories: “inappropriate drug choice,”
“suboptimal formulation” and “unclear documentation”
had the lowest acceptance rate. However, unclear
documentation was rare among nursing home
patients. In home nursing care, “adverse reactions,”
“interaction” and “monitoring required” tended to be
the least accepted DRPs (Figure 1).
Discussion
Main findings
Drug choice problems: “unnecessary drug,” “need for
additional drug”, “inappropriate drug choice,” in add-
ition to “unclear documentation” accounted for the
majority of the DRPs found in this study. Patients
Table 2. Identified and classified DRPs in nursing homes and home nursing care, per patient.
DRP Category
Total sample (N¼ 154) Nursing home (n¼ 61) Home nursing care (n¼ 93)
P-valueaCount Mean Median IQR Count Mean Median IQR Count Mean Median IQR
Total number of DRP 740 4.8 4.0 4.0 227 3.7 3.0 3.0 513 5.5 4.0 4.0 0.002
Drug choice
Need for additional drug 83 0.54 0.0 1.0 49 0.80 0.0 2.0 34 0.37 0.0 1.0 0.001
Unnecessary drug 132 0.86 1.0 1.0 63 1.03 1.0 2.0 69 0.74 0.0 1.0 0.109
Inappropriate drug choice 76 0.49 0.0 1.0 22 0.36 0.0 0.5 54 0.58 0.0 1.0 0.242
Dosing
Too high dose 63 0.41 0.0 1.0 19 0.31 0.0 0.0 44 0.47 0.0 1.0 0.151
Too low dose 19 0.12 0.0 0.0 6 0.10 0.0 0.0 13 0.14 0.0 0.0 0.500
Sub-optimal dosing scheme 11 0.07 0.0 0.0 5 0.08 0.0 0.0 6 0.06 0.0 0.0 0.710
Sub-optimal formulation 18 0.12 0.0 0.0 11 0.18 0.0 0.0 7 0.08 0.0 0.0 0.280
Adverse reactions 33 0.21 0.0 0.0 8 0.13 0.0 0.0 25 0.27 0.0 0.5 0.060
Interactions 50 0.32 0.0 0.0 17 0.28 0.0 0.0 33 0.35 0.0 0.5 0.520
Drug use
Inappropriate use by health personal 3 0.02 0.0 0.0 0 – – – 3 0.02 0.0 0.0 0.158b
Inappropriate use by patient 1 0.01 0.0 0.0 1 0.01 0.0 0.0 0 – – – 0.217b
Other
Monitoring required 37 0.24 0.0 0.0 13 0.21 0.0 0.0 24 0.26 0.0 0.0 0.650
Unclear documentation 209 1.36 0.0 1.0 9 0.15 0.0 0.0 200 2.15 1.0 2.5 0.000
Not classified/complex problem 5 0.03 0.0 0.0 4 0.07 0.0 0.0 1 0.01 0.0 0.0 0.061b
aStudent’s t-test for Mean
bMann-Whitney U test for Median; IQR: Interquartile range
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receiving home nursing care had significantly more
DRPs compared to patients living in nursing homes.
The categories “need for additional drug” and “unclear
documentation” differed significantly between the groups.
“The need for additional drug” was particularly frequent
in nursing homes and “unclear documentation” was most
frequent in patients receiving home nursing care.
Patients in home nursing care also had more prob-
lems regarding too high doses and adverse reactions,
although neither were statistically significant. In the
total sample, GPs accepted 70.0% of the DRPs and
made subsequent changes to the patient’s medication
regimens. The acceptance rate was 71.8% in nursing
homes and 69.2% in home nursing care. Among the
most frequently detected DRPs, “inappropriate drug
choice” had the lowest acceptance rate in nursing
homes, while ‘adverse reactions’ had the lowest
acceptance rate in home nursing care.
Table 3. Proportions of accepted DRPs in nursing homes and home nursing care.
DRP Category
Total sample Nursing home Home nursing care
Detected Count
Accepted
Detected Count
Accepted
Detected Count
Accepted
% 95% CI (%) 95% CI (%) 95% CI
All categories 740 70.0 66.7–73.3 227 71.8 66.0–77.6 513 69.2 65.2–73.2
Drug choice
Need for additional drug 83 77.1 68.1–86.1 49 79.6 68.3–90.9 34 73.5 58.7–88.3
Unnecessary drug 132 73.5 65.0–81.0 63 76.2 65.7–86.7 69 71.0 60.3–81.7
Inappropriate drug choice 76 50.0 38.8–61.2 22 50.0 29.1–70.9 54 50.0 36.7–63.3
Dosing
Too high dose 63 66.7 55.0–78.3 19 73.7 53.9–93.5 44 63.6 49.4–77.8
Too low dose 19 78.9 60.6–99.3 6 100 – 13 69.2 44.2–94.3
Sub-optimal dosing scheme 11 100 – 5 100 – 6 100 –
Sub-optimal formulation 18 55.6 32.6–78.5 11 45.5 16.0–78.9 7 71.4 38.0–104.9
Adverse reaction 33 42.4 25.6–59.3 8 75.0 45.0–105.0 25 32.0 13.7–48.3
Interaction 50 60.0 46.4–73.6 17 82.4 64.2–100.5 33 48.4 31.4–65.5
Drug use
Inappropriate use by health personal 3 100 – – – – 3 100 –
Inappropriate use by patient 1 100 – 1 100 – – – –
Other
Monitoring required 37 56.8 40.8–97.5 13 69.2 44.2–94.3 24 50.0 30.0–70.0
Unclear documentation 209 80.9 75.5–86.2 9 33.3 2.5–64.1 200 83.0 77.8–88.2
Not classified/complex problem 5 80.0 44.9-115.1 4 75.0 32.6–117.4 1 100 –
CI¼ Confidence Interval.
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Figure 1. Proportions of accepted DRPs (%). Error bars represent 95% confidence intervals.
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Strengths and limitations
Over the years, over 20 classifications systems have
been developed for the identification of DRPs [24].
Having so many competing classifications systems,
however, makes it difficult to compare results and to
detect differences between patients and their exposure
to unsafe drug treatments. We believe this study to be
of particular importance given that few other studies
that attempted to draw these comparisons. At the
same time, there are several limitations in this study.
Data collection in this study did not include regis-
tration of the pharmacological names of all regular
drugs. The number of drugs used was registered, but
only those drugs identified as have caused a DRP
were registered by pharmacological labels. Moreover,
neither the patients’ diagnoses nor clinical conditions
were included in the data. Still, the number of regular
drugs used by our participants was congruent
with other studies [3,5,6,8,25–30], thus suggesting that
our sample had a comparable level of comorbidity.
Different GPs, nurses and pharmacists performed
the medication reviews. The influence of individual
professional experiences and judgements must be
taken into account when considering the results. The
generalisability of the results is also affected by the
sampling of patients, as performed by the liable pro-
fessionals at the respective units. However, the inten-
tion was to describe the findings and variations of
DRPs as identified by different clinicians collaborating
in teams. Obviously, a number of factors can come
together and bias these findings, including the know-
ledge and experience of the professionals and the
quality of documentation. On the other hand, object-
ive clinicians would be restricted to identify DRPs on
the basis of written information in patient records
without necessarily knowing the patient’s personal his-
tory, preferences, earlier reactions to treatment, symp-
toms and daily functioning – information that, in the
authors’ experiences, may be poorly documented in
the records. In our opinion, the probability of
identified DRPs being clinically relevant increases
when local professionals perform such reviews as
compared with reviews done by more detached
objective clinicians. Additionally, every local team con-
sisted of members who had received unitary training
in detecting DRPs by participating in the Patient safety
Programme.
Another limitation of this study was the uses of
retrospective data collection. Using this approach, our
data was limited only what local professionals had
documented in their journals. Thus, the researchers
had restricted information about the discussions that
took place at the case conferences. In addition, docu-
mentation quality varied. The presence of a pharma-
cist in each team provided for a more standardised
and structured approach to documentation as com-
pared to teams consisting simply of GPs and nurses.
Findings in relation to other studies
Compared to other studies using similar classification
tools, the frequency of DRPs found in the total sample
is consistent with studies by Leikola et al. [25] and
Halvorson et al [26], although greater than what
others have detected [27–31]. Of the corresponding
research, only Leikola et al. [25] and Milos et al. [30]
included patients from both home nursing care and
assisted-living/nursing homes. Aligned with our results,
Leikola et al. [25] found that DRPs were more common
in the homecare setting than in assisted-living,
whereas DRPs did not differ in nature across the two
settings. Milos et al. [30] found no differences between
the number of DRPs in community-dwelling patients
and in nursing home patients.
Much like the findings of the present, comparable
studies covering both healthcare settings found a
high frequency of drug choice problems (e.g.
unnecessary drug, inappropriate drug choice) along
with dosing problems (most often dosage that was
too high) [25–27,30]. However, there is partial sup-
port in the literature for disparities in terms of the
type of DRPs found between patient groups. Adverse
reactions and too high doses were commonly identi-
fied among patients in home nursing care [28,29],
but unclear documentation is seldom highlighted as
a unique DRP. As opposed to the Norwegian tool,
most classification systems define unclear documen-
tation as a potential cause of DRP and not a DRP in
itself [24]. Therefore, findings related to divergence
between different medication lists, incorrect, unclear
or omitted information about indication, doses, dos-
ing scheme etc. may be classified under different
labels or aggregated and reflected by another over-
riding category. Among comparable studies, only
Halvorsen et al. [26] used the Norwegian tool with-
out modification, reporting that unclear documenta-
tion accounted for 16% of the DRPs in nursing
homes. In comparison, the present study found that
documentation problems accounted for 4% of DRPs
in nursing homes and 39% of DRPs in home nursing
care. Brody et al. [32] also stresses the frequency of
medication discrepancies in the homecare setting; all
770 patients referred from hospital to homecare
services had medication discrepancies, whereas
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90.1% of the lists had omissions and 71% contained
dosing discrepancies. Problems with unintended
medication discrepancies that occur when patients
transfer between different care levels or therapists
are widely reported, however these are claimed to
have little clinical significance [33]. Others [34] show
that medication discrepancies increase the risk of
hospital admissions and that older patients who lack
social supports may be particularly vulnerable (e.g.
older patients living alone). The problem is topical in
the homecare setting where GPs and nurses often
work in suboptimal systems concerning the safe and
adequate exchange of information [16–18].
Incomplete medical records and errors propagating
in time and systems clearly represent threats to
patients’ safety as well as to professionals’ decision-
making [27]. Acknowledging unclear documentation
as a significant DRP may be the first step towards
raising awareness around this issue and improving
the quality of care.
Halvorsen et al. [12] found that drug-prescribing
quality differed between patients receiving home nurs-
ing care and nursing home patients. Compared with
nursing homes, patients in home nursing care used
more cardiovascular drugs and fewer psychotropic
drugs, and drug-to-drug interactions were identified
more frequently in home nursing care. As we did not
register all pharmacological names (i.e. active ingre-
dients) for the drugs used by patients, we must be cau-
tious when considering the prescribing quality in our
sample. Notwithstanding, psychotropic drugs were
involved in the majority of detected DRPs in this study,
and these drugs were at least as common in the home-
care settings as in the nursing homes. Drugs in this cat-
egory typically increase the risk of gait instability, falls,
fractures and cognitive decline in older patients [12].
Like Halvorsen et al. [12] we found a higher numbers of
interactions (drug–drug) among patients in home nurs-
ing care than in nursing homes, although this difference
was not statistically significant.
The proportion of identified DRPs that led to medi-
cation changes in the total sample (70.0% agreement)
was higher in this study than in other studies, where
agreement ranges 55%–66% [25–27,30]. This differ-
ence is most likely a product of the DRP tool itself,
because if the DRP category “unclear documentation”
had been excluded, the mean acceptance rate would
be 58%. Additionally, the likelihood of agreement
might be higher in teams consisting of local health
professionals who have direct knowledge of their
patients as compared to reviews done by object-
ive clinicians.
In both settings, a low acceptance rate was seen
concerning inappropriate drug choices. Moreover, the
acceptance rate for adverse reactions in home nursing
care was especially low. Inappropriate drugs are
defined as drugs with a low benefit-to-risk-ratio, uncer-
tain effects or that have the potential to cause adverse
reactions in excess of clinical benefits [35]. Several sets
of explicit quality indicators have been developed to
assess the quality of prescriptions for older people, but
do not seem to have reached intended goals yet [36].
Clearly, a range of factors influences the decision-
making process with respect to the prescription or
withdrawal of potentially inappropriate medications,
including patient-oriented prioritisation, knowledge,
experience and organisational characteristics of their
daily practice [37]. Making patient-oriented prioritisa-
tions demands that the prescriber has adequate know-
ledge about patients and their situations. In home
nursing care especially, the lack of contact between
physicians and their patients considerably increases
nurses’ responsibility to observe, assess and transfer
information. Moreover, organisational characteristics in
both settings can challenge the information-flow and
opportunities to have interprofessional discussions.
Collaboration with pharmacists is expected to increase
the knowledge and awareness of doctors and nurses
concerning DRPs [26]. As such, the high number of
DRPs found by teams without pharmacists represents
an unexpected finding. Notwithstanding, a high num-
ber of DRPs detected does not grant support for either
the quality of the review or the clinical relevance of the
problems being detected. On the one hand, pharma-
cists may lack clinical knowledge about patients’ daily
functioning (knowledge possessed by GPs and nurses);
on the other hand, pharmacists have pharmaceutical
expertise that exceeds that of the other professionals
involved in the care of such patients. Pharmacist
interventions and their clinical collaboration with
other healthcare professionals in the community is
thought to be a powerful force for improving medica-
tion safety [25,26]. However, other studies report
incongruent findings with respect to if and how
the number of DRPs identified is related to the per-
spectives of the professionals employed to detect
them [25–30].
The variations of DRPs found across the two care
settings in this study, raises perhaps more questions
than answers. Most importantly, the findings highlight
differences, thus indicating that the homecare setting
may be just as critical as nursing homes are believed
to be when it comes to suboptimal medica-
tion therapy.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE 7
Conclusions and further research
The results of this research showed that DRPs differ in
both number and nature across the two care settings:
nursing homes and home nursing care. The frequency
by which unclear documentation and the numbers of
adverse reactions were found in the homecare setting
is troubling and of particular interest in light of the
trend towards an increasingly aging population with
older persons preferring to be cared for in their own
homes. Actions to improve documentation discrepan-
cies in the homecare setting are therefore urgent.
Further research is warranted to explore how different
care settings might influence drug safety among
older patients.
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Notes
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2. ATC, the Anatomical Therapeutic Chemical System.
WHO. http://www.who.int/classifications/atcddd/en/
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